The collaboration combines XtalPi’s AI algorithm, molecular modeling & automated experiments to develop an AI tumor vaccine R&D platform & design capabilities of tumor vaccines to activate specific immune responses to kill tumors, accelerate the R&D process, improve the success rate & efficacy of tumor vaccines
The platform is designed to provide a preclinical tumor vaccine candidate compound with robust immune activity. Tumor vaccines targeting various tumor neoantigens, TAA, and TSA in patients can be created for use as immunotherapy triggering the patient’s immune responses
Two therapeutic tumor vaccines are currently available i.e., sipuleucel-T for melanoma & BCG for bladder cancer along with preventive tumor vaccines against HPV & hepatitis B inf.
Ref: PRNewswire | Image: CK Life Sciences
